Neue Wege zur Therapie gegen Alzheimer

London, UK, Göttingen, Germany, 24.07.2015

MBM ScienceBridge GmbH, Georg-August-University Göttingen, University Medical Center  and MRC Technology a UK medical research charity, are collaborating on new therapy for neurodegenerative diseases.

MBM ScienceBridge GmbH, Georg-August-University Göttingen, University Medical Center and MRC Technology, a UK medical research charity, have signed an exclusive license agreements for the development of a novel therapy of neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x. The aim is to develop a therapy for Alzheimer's Disease (AD).

The licence negotiated by MBM ScienceBridge GmbH, the technology transfer organization of the Georg-August-Universität Göttingen, will enable UMG to access the world-class antibody humanization expertise of MRCT’s Centre for Therapeutics Discovery and the work of its Therapeutic Antibody Group, led by Dr David Matthews and gives MRCT the opportunity to use its renowned capability to take lab tool compounds and turn them into clinical candidates, which will then be licensed to the pharmaceutical and biotech industry.

MRCT receives an exclusive worldwide license to the IP rights of UMG related to a novel therapeutic approach for the treatment of sporadic and familial AD, based on a panel of unique antibodies developed by its scientist Prof. Dr. Thomas Bayer. MRCT and UMG will then receive downstream payments dependent on the successful development and out-licensing of the antibody. This income will be used for further research within the organisations.

Notes to Editors

Media Contacts:
MBM ScienceBridge GmbH
E-mail: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!, Phone: +49-551-30724150
Website: www.sciencebridge.de

MRC Technology
Liezel Tipper PR & Communications Manager, MRC Technology
E-mail: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!, Phone: +44(0) 20 7391 2772